At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Botulinum Toxin Type B (Myobloc) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC·interventional·Posted Aug 13, 2007·Updated Apr 21, 2026
In Brief
A Phase 2 clinical trial evaluating Botulinum Toxin Type B (Myobloc) and Matched placebo to Myobloc for Drooling. Completed, enrolled 54 participants across 18 sites.
Detailed Summary
To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrooling
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedAug 2007
Primary CompletionJun 2008
Study CompletionSep 2008
TodayJul 2026
First PostedAug 13, 2007
Enrollment StartJul 1, 2007
Primary CompletionJun 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.9 years ago
Interventions
Botulinum Toxin Type B (Myobloc)biological
Matched placebo to Myoblocbiological